Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Date of Report: May 15, 2019
Reporting Period: The filing primarily reports on a material definitive agreement executed on May 15, 2019. It also references the Company's financial and operating results for the first quarter ended March 31, 2019, via a press release incorporated by reference.
Key Financial Metrics and Capital Structure
This filing details a new financing arrangement rather than standard quarterly financial statements. Key metrics include:
- Financing Commitment: Lincoln Park Capital Fund, LLC committed to purchase up to $20,000,000 of the Company's common stock.
- Initial Issuance: On the execution date, the Company issued 66,667 shares as commitment shares and sold an additional 33,333 shares for an aggregate consideration of $300,000.
- Stock Outstanding: Approximately 2,026,936 shares were outstanding immediately prior to the execution of the agreement.
- Base Price: Defined as $11.2884 (average closing price for the five trading days preceding execution plus an incremental amount).
- Revenue/Profit/Cash Flow: The filing text does not provide specific values for revenue, net income, operating cash flow, or margins for the quarter ended March 31, 2019; these are contained in the referenced press release (Exhibit 99.1).
Material Changes and Agreement Terms
The primary material change is the entry into a Purchase Agreement and Registration Rights Agreement with Lincoln Park Capital Fund, LLC. Key terms include:
- Duration: The agreement allows for sales over a 24-month period commencing on the "Commencement Date" (when SEC registration conditions are met).
- Purchase Mechanics:
- Regular Purchases: The Company may direct Lincoln Park to purchase up to 20,000 shares per day (capped at $1,000,000 per day). This limit increases to 30,000, 40,000, or 50,000 shares if the closing price is above $8.00, $10.00, or $12.00, respectively.
- Pricing: Based on prevailing market prices immediately preceding the sale with no fixed discount, subject to a floor price.
- Accelerated Purchases: Available if the stock price exceeds certain thresholds.
- Exchange Cap: The Company cannot issue more than 19.99% of pre-transaction outstanding shares (approx. 405,142 shares) without stockholder approval or unless the average sale price exceeds the Base Price.
- Beneficial Ownership Limit: Sales are restricted if they would cause Lincoln Park to beneficially own more than 4.99% of the Company's common stock.
Outlook, Risks, and Management Commentary
- Use of Proceeds: The Company expects to use proceeds for general corporate purposes, specifically to advance its drug development pipeline.
- Discretionary Nature: The Company has the right, but not the obligation, to sell shares. Lincoln Park is obligated to purchase as directed, subject to conditions.
- Termination: The Company may terminate the agreement at any time without cost or penalty. The agreement automatically terminates in the event of bankruptcy proceedings.
- Risks: Actual proceeds depend on market conditions and the Company's determination of funding needs. The agreement includes a covenant preventing Lincoln Park from short selling or hedging the Company's shares.
- Variable Rate Transactions: The Company agreed not to enter into other "variable rate" transactions with third parties for a defined period.
Investor Verification Checklist
- Verify the specific financial results (revenue, cash burn, net loss) for Q1 2019 in the press release attached as Exhibit 99.1, as this 8-K does not contain the numerical data.
- Monitor the "Commencement Date" to determine when the Company can begin selling shares under the $20 million facility.
- Track the Company's stock price relative to the $8.00, $10.00, and $12.00 thresholds to understand potential daily sale volume limits.
- Review the 19.99% Exchange Cap to assess the maximum dilution potential without shareholder approval.
- Confirm the status of the registration statement filed with the SEC to ensure the facility is active.